FibroBiologics, Inc. Common Stock (FBLG) earnings · last reported Jul 31, 2026
Next report
Around Tue, Feb 23, 2027
In 111 days · quarter ending Dec 2026
Not announced yet. Lician projection, not a company or provider date: the same quarter’s report a year ago plus 52 weeks.
Follow FBLG into its report
Save it to a free watchlist (no card). Alerts when the date moves or results land are part of Pro.
Earnings move
- Options price in
- — No upcoming report date.
- Average move after earnings
- ±7.3% Absolute close-to-close move, 2 reports
Options-implied move: the at-the-money straddle (call + put) on the first expiry after the report, divided by the stock’s close, from EODHD end-of-day option chains. It is what the options market prices as the absolute move to that expiry, not a forecast of direction. Move: close before the news → close after it (before the open: prior close → report-day close; after the close: report-day close → next close), adjusted for splits and dividends, from EODHD end-of-day prices. Reports with an unannounced time are not averaged: both candidate moves are stored instead. Per-report moves, gaps, moves vs SPY and the sector, beat/miss asymmetry and implied vs actual are in Lician Pro below.
Latest result
EPSGAAP
−$0.66
vs −$0.93 est. +29.0%
GAAP diluted EPS, SEC 10-Q
Revenue
—
No revenue consensus stored
EPS actuals are checked against the SEC filing and the company’s earnings press release (8-K EX-99.1). A company that reports only GAAP EPS is graded on its SEC diluted EPS; one that reports adjusted EPS is graded on the provider’s adjusted figure when the release confirms it. A figure that matches neither is shown as unverified, with no beat or miss. Revenue actuals come from the SEC filing of the same quarter where we have it.
Beat / miss history
- Beat EPS 2 quarters in a row
- Beat EPS in 2 of 2
- Jul 31, 2026BeatEPS −$0.66GAAP vs −$0.93 +29.0%Rev — vs —
- May 1, 2026BeatEPS −$1.33GAAP vs −$1.36 +1.8%Rev — vs —
- May 29, 2024EPS −$0.27GAAP vs — —Rev — vs —
| Reported | Quarter | EPS est. | EPS actual | Surprise | Revenue est. | Revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | Jun 2026 | −$0.93 | −$0.66GAAP | +29.0% | — | — | — |
| May 1, 2026 | Mar 2026 | −$1.36 | −$1.33GAAP | +1.8% | — | — | — |
| May 29, 2024 | Mar 2024 | — | −$0.27GAAP | — | — | — | — |
Only 3 reported quarters are stored for FBLG so far. Older quarters are added as we load each company’s earnings history; nothing is filled in by estimate.
Earnings documents
No earnings 8-K (item 2.02) is stored for this report yet. All FBLG filings: SEC filings.
Documents link to SEC EDGAR. Lician does not publish earnings-call transcripts.
Healthcare peers with similar quant ratings
FBLG among 532 rated Healthcare stocks (Lician quant rating, Nov 4, 2026). How the rating works
- QTTB earnings5.00 · Strong Buy · stock
- AVAH earnings4.99 · Strong Buy · stock
- CDNA earnings4.98 · Strong Buy · stock
- HALO earnings4.97 · Strong Buy · stock
- OSCR earnings4.97 · Strong Buy · stock
- REGN earnings4.95 · Strong Buy · stock
- CON earnings4.94 · Strong Buy · stock
- PACS earnings4.94 · Strong Buy · stock
| Quarter | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 FY26 | — | −$0.66 | — |
| Q1 FY26 | — | −$1.33 | — |
| Q3 FY25 | — | −$0.13 | — |
| Q2 FY25 | — | −$0.12 | — |
FibroBiologics, Inc. Common Stock (FBLG) is a biotechnology company listed on US.
No cached income statement for FBLG yet, so there is no earnings base to recap.
When the next FBLG 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
Period-over-period revenue change is not in cache for FBLG. We will not invent a beat or miss.
Not investment advice. Full FBLG research stays on the stock page; the tape stays on the quote page.
FBLG earnings FAQ
When is FBLG's next earnings date?
FibroBiologics, Inc. Common Stock (FBLG) has not announced it yet. Lician estimates the next report around Feb 23, 2027, based on the date it reported the same quarter a year ago. This is an estimate, not a confirmed date; the page updates when the provider lists one.
Did FBLG beat earnings estimates last quarter?
Yes. On Jul 31, 2026 FibroBiologics, Inc. Common Stock (FBLG) reported adjusted EPS of −$0.66 against a −$0.93 consensus (+29.0%), a beat.
How often does FBLG beat EPS estimates?
FibroBiologics, Inc. Common Stock (FBLG) beat the EPS consensus in 2 of its last 2 reported quarters.
Not investment advice.